Egr1在肝癌中的研究进展

doi:10.11904/j.issn.1002-3070.2022.05.008

Abstract

Abstract: Liver cancer is a common malignant tumor in the world.Most patients with liver cancer were in the middle and late stages when diagnosed.Early growth response factor 1(Egr1)is a transcription factor that is induced during liver injury and regulates the expression of genes involved in cell proliferation,involved in cell proliferation and the role of Egr1 in liver injury and repair,and the lack of Egr1 will delay the process of liver regeneration.Recent studies have emphasized the dual role of Egr1 in the occurrence,development and treatment of liver cancer,thus affecting the progress of liver cancer.This article reviews the possible role of Egr1 in the occurrence,development and treatment of liver cancer,and analyzes in details the complex signal pathways involved by Egr1,so as to provide reference for clinical efficacy prediction and discovery of new therapeutic targets.

Key words: Egr1, Liver cancer, Occurrence and development, Treatment

CLC Number:

R735.7

SUN Xinglu, CHEN Che. Research progress of Egr1 in liver cancer[J]. Journal of Practical Oncology, 2022, 36(5): 435-439.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.05.008

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I5/435

References

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer Clin,2021,71(3):209-249.
2 Wang B,Guo H,Yu H,et al.The role of the transcription factor EGR1 in cancer[J].Front Oncol,2021,11:642547.
3 Marignol L,Coffey M,Hollywood D,et al.Radiation to control transgene expression in tumors[J].Cancer Biol Ther,2007,6(7):10-12.
4 Bhattacharyya S,Fang F,Tourtellotte W,et al.Egr1:new conductor for the tissue repair orchestra directs harmony(regeneration)or cacophony(fibrosis)[J].Pathol,2013,229(2):86-97.
5 Li TT,Liu MR,Pei DS.Friend or foe,the role of Egr1 in cancer[J].Med Oncol,2019,37(12):7.
6 Duclot F,Kabbaj M.The role of early growth response 1(Egr1)in brain plasticity and neuropsychiatric disorders[J].Front Behav Neurosci,2017,6(5);11:35.
7 Swirnoff AH,Apel ED,Svaren J,et al.Nab1,a corepressor of NGFI-A(Egr1),contains an active transcriptional repression domain[J].Mol Cell Biol,1998,18(1):12-24.
8 Sevetson BR,Svaren J,Milbrandt J.A novel activation function for NAB proteins in EGR dependent transcription of the luteinizing hormone beta gene[J].Biol Chem,2000,275(13):49-57.
9 Kang HS,Ock J,Lee HJ,et al.Early growth response protein 1 upregulation and nuclear translocation by 2'-benzoyloxycinnamaldehyde induces prostate cancer cell death[J].Cancer Lett,2013,329(2):17-27.
10 Choi EJ,Yoo NJ,Kim MS,et al.Putative tumor suppressor genes Egr1 and BRSK1 are mutated in gastric and colo-rectal cancers[J].Oncology,2016,91(5):289-294.
11 Sun M,Nie FQ,Zang C,et al.The pseudogene DUXAP8 promotes non-small-cell lung cancer cell proliferation and invasion by epigenetically silencing EGR1 and RHOB[J].Mol Ther,2017,25(3):739-751.
12 Bi JG,Zheng JF,Li Q,et al.MicroRNA-181a-5p suppresses cell proliferation by targeting Egr1 and inhibiting Egr1/TGF-β/Smad pathway in hepatocellular carcinoma[J].Int Biochem Cell Biol,2019,106(1):107-116.
13 Gong D,Zeng Z,Yi F,et al.Inhibition of histone deacetylase 11 promotes human liver cancer cell apoptosis[J].Am Transl Res,2019,11(2):983-990.
14 Inoue K,Fry EA.Tumor suppression by the EGR1,DMP1,ARF,p53,and PTEN Network[J].Cancer Invest,2018,36(9/10):520-536.
15 Shin DY,Kim GY,Kim ND,et al.Induction of apoptosis by pectenotoxin-2 is mediated with the induction of DR4/DR5,Egr1 and NAG-1,activation of caspases and modulation of the Bcl-2 family in p53 deficient Hep3B hepatocellular carcinoma cells[J].Oncol Rep,2008,19(2):17-26.
16 Baek SJ,Kim JS,Nixon JB,et al.Expression of NAG-1,a transforming growth factorbeta superfamily member,by troglitazone requires the early growth response gene Egr1[J].Biol Chem,2004,279(8):83-92.
17 Chintharlapalli S,Papineni S,Baek SJ,et al.1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl)methanes are peroxisome proliferator-activated receptor gamma agonists but decrease HCT-116 colon cancer cell survival through receptor independent activation of early growth response-1 and nonsteroidal anti-inflammatory drug-activated gene-1[J].Mol Pharmacol,2005,68(6):82-92.
18 Gong D,Zeng Z,Yi F,et al.Inhibition of histone deacetylase 11 promotes human liver cancer cell apoptosis[J].Am Transl Res,2019,11(2):983-990.
19 Ao H,Liu B,Li H,et al.Egr1 mediates retinal vascular dysfunction in diabetes mellitus via promoting p53 transcription[J].Cell Mol Med,2019,23(5):3345-3356.
20 Liedtke C,Trautwein C.The role of TNF and Fas dependent signaling in animal models of inflammatory liver injury and liver cancer[J].Eur Cell Biol,2012,91(6/7):582-589.
21 Jing Z,Ye X,Ma X,et al.SNGH16 regulates cell autophagy to promote sorafenib resistance through suppressing miR-23b-3p via sponging Egr1 in hepatocellular carcinoma[J].Cancer Med,2020,9(12):4324-4338.
22 Oliveto S,Mancino M,Manfrini N,et al.Role of microRNAs in translation regulation and cancer[J].World Biol Chem,2017,8(1):45-56.
23 Zhang L,Ren R,Yang X,et al.Oncogenic role of early growth response-1 in liver cancer through the regulation of the microRNA-675/sestrin 3 and the Wnt/β-catenin signaling pathway[J].Bioengineered,2021,12(1):5305-5322.
24 Li H,Li J,Jia S,et al.miR675 upregulates long noncoding RNA H19 through activating Egr1 in human liver cancer[J].Oncotarget,2015,6(11):58-84.
25 Bellam N,Pasche B.Tgf-beta signaling alterations and colon cancer[J].Cancer Treat Res,2010,155:85-103.
26 Matsuzaki K.Smad phosphoisoform signaling specificity:the right place at the right time[J].Carcinogenesis,2011,32(11):78-88.
27 Gilliam DT,Menon V,Bretz NP,et al.The CD24 surface antigen in neural development and disease[J].Neurobiol Dis,2017,99(3):133-144.
28 Li L,Chen J,Ge C,et al.CD24 isoform a promtes cell proliferation,migration and invasion and is downregulated by EGR1 in hepatocellular carcinoma[J].Onco Targets Ther,2019,12(2):1705-1716.
29 He S,Zhong Y,Shuai C,et al.Tumor suppressor NGX6 inhibits the growth and metastasis of multiple cancers[J].Tumour Biol,2016,37(5):5751-5760.
30 García-Vilas JA,Medina Má.Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications[J].World Gastroenterol,2018,24(33):3695-3708.
31 Zhang YW,Su Y,Volpert OV,et al.Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation[J].Proc Natl Acad Sci U S A,2003,100(22):12718-12723.
32 Lee KH,Kim JR.Hepatocyte growth factor induced up-regulations of VEGF through Egr1 in hepatocellular carcinoma cells[J].Clin Exp Metastasis,2009,26(7):85-92.
33 He S,Zhong Y,Shuai C,et al.Tumor suppressor NGX6 inhibits the growth and metastasis of multiple cancers[J].Tumour Biol,2016,37(5):51-60.
34 Liu M,Wang X,Peng Y,et al.Egr1 regulates the transcription of NGX6 gene through a Sp1/Egr1 overlapping site in the promoter[J].BMC Mol Biol,2014,16(7):15:14.
35 Chen M,Wei L,Law CT,et al.RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2[J].Hepatology,2018,67(6):2254-2270.
36 Lei T,Zhu X,Zhu K,et al.EGR1-induced up-regulation of lncRNA FO-D2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating wnt/β-catenin signaling pathway[J].Cancer Biol Ther,2019,20(7):1007-1016.
37 Zhang L,Ren R,Yang X,et al.Oncogenic role of early growth response-1 in liver cancer through the regulation of the microRNA-675/sestrin 3 and the Wnt/β-catenin signaling pathway[J].Bioengineered,2021,12(1):5305-5322.
38 Li X,Yu J,Brock MV,et al.Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU[J].Oncotarget,2015,6(13):11547-11560.
39 Lin M,Huang J,Zhang J,et al.The therapeutic effect of PEI-Mn_0.5Zn_0.5Fe₂O₄ nanoparticles/pEgr1-HSV-TK/GCV associated with radiation and magnet-induced heating on hepatoma[J].Nanoscale,2013,5(3):991-1000.
40 Mei Lin,Zhang DS,Huang JX,et al.An evaluation on transfection efficiency of pHRE-Egr1-EGFP in hepatocellular carcinoma cells bel-7402 mediated by PEI-MZF-NPs[J].Nanomater,2011,23(1):242-248.
41 Hallahan DE,Mauceri HJ,Seung LP,et al.Spatial and temporal control of gene therapy using ionizing radiation[J].Nat Med,1995,1(8):86-91.
42 Liu Y,Wu MC,Qian GX.The experimental study of anti-human AFP variant Mc-Ab in radioimmuno-detection and radioimmuno-therapy of human hepatocellular carcinoma model in nude mice[J].Zhonghua Wai Ke Za Zhi,1994,32(11):650-653.
43 Loutski M,Remold-O'Donnell E,Roumiantsev AG,et al.Regulation of anti-tumor activity using monoclonal anti-bodies to alpha-fetoprotein receptor and after immunization with this protein[J].Russ Immunol,2001,6(3):257-264.
44 Lin M.Radio nuclide immune albumin nanospheres(¹³¹I-antiAFPMcAb-GCV-BSA-NPs):preparation and hepatoma targeting in vitro and in vivo[J].ACP,2016,91:42198.
45 Lin M,Huang J,Jiang X,et al.A combination hepatom a targeted therapy based on nanotechnology:pHRE-Egr1-HSV-TK/¹³¹I-antiAFPMc-Ab-GCV/MFH[J].Sci Rep,2016,6:33524.
46 Trusolino L,Bertotti A,Comoglio PM.MET signalling:principles and functions in development,organ regeneration and cancer[J].Nat Rev Mol Cell Biol,2010,11(12):34-48.
47 Bouattour M,Raymond E,Qin S,et al.Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma[J].Hepatology,2018,67(3):1132-1149.
48 Chen HA,Kuo TC,Tseng CF,et al.Angiopoietin-like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma[J].Hepatology,2016,64(5):1637-1651.
49 Xiang QF,Zhan MX,Li Y,et al.Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway[J].Artif Cells Nanomed Biotechnol,2019,47(1):83-89.

[1]	WANG Xinghan, LV Yalei. Mechanisms of trastuzumab resistance and post-resistance treatment strategies in HER2-positive breast cancer [J]. Journal of Practical Oncology, 2022, 36(5): 445-451.
[2]	NA Jun, AN Xiaoxia, LI Xun, ZHANG Weiwei, MU Huijuan, LI Yanxia, PAN Guowei, LIU Li. Analysis of 10-year survival rate of liver cancer among residents in three cities of Liaoning province from 2000 to 2002 [J]. Journal of Practical Oncology, 2022, 36(4): 293-298.
[3]	LI Lei, ZHANG Lei, CHENG Wen. Application and progress of ultrasound-guided thermal ablation of liver cancer [J]. Journal of Practical Oncology, 2022, 36(4): 386-390.
[4]	LI Bo, PENG Xiaolin, WANG Shanshan, LI Gairui, ZHAO Dan, PENG Ji. Comparative study on application effect of two risk assessment models in screening colorectal cancer [J]. Journal of Practical Oncology, 2022, 36(3): 197-202.
[5]	TANG Rubing, WANG Qi, YOU Xuemei. Research progress in molecular mechanism of liver cancer comorbid and depression [J]. Journal of Practical Oncology, 2022, 36(3): 239-244.
[6]	WANG Yang, LI Guodong, TANG Qingchao, LIU Ming. Research progress of acidosis in colorectal malignant tumors [J]. Journal of Practical Oncology, 2022, 36(1): 74-78.
[7]	LI Yujun, LIU Liyang, XIAO Juanjuan, XUE Hua. Prognostic stratification and treatment progress in elderly patients with newly diagnosed multiple myeloma [J]. Journal of Practical Oncology, 2022, 36(1): 84-88.
[8]	TUO Jiyu, ZHANG Xia, HE Xiaomei, JIANG Wenzhen, FENG Jueping, JIN Xia, ZHANG Min, WEI Shaozhong. Analysis of the screening results of the urban cancer early diagnosis and treatment project in Hubei province from 2018 to 2019 [J]. Journal of Practical Oncology, 2021, 35(4): 297-301.
[9]	LI Qingyu, YANG Lei, ZHANG Xi, LIU Shuo, LI Huichao, ZHANG Qian, CHENG Yangyang, JI Jiafu, WANG Ning. Discussion on the management of early diagnosis and treatment for cancer under the coronavirus disease(COVID-19) [J]. Journal of Practical Oncology, 2021, 35(4): 302-306.
[10]	ZHU Yunfang, CHEN Yang, ZHU Linfang, SHI Qingping, CHENG Huirong, REN Siying, WEN Hongmei. The incidence and mortality of liver cancer in Yunnan cancer registration areas in 2016 and the change trend from 2011 to 2016 [J]. Journal of Practical Oncology, 2021, 35(2): 97-102.
[11]	HU Qihui, DU Yichao, HE Kai, FU Wenguang, XIA Xianming. The role of endoplasmic reticulum stress in liver cancer [J]. Journal of Practical Oncology, 2021, 35(2): 160-164.
[12]	HU Yang, ZHANG Qingyuan. Research progress of PARP inhibitors in the treatment of BRCA1/2 mutation metastatic breast cancer [J]. Journal of Practical Oncology, 2021, 35(2): 184-187.
[13]	BI Jiaqing, QIN Qian, MA Huihan, MA Meijie, FENG Qinmei. Research progress of threonine and tyrosine kinase in tumor [J]. Journal of Practical Oncology, 2021, 35(2): 188-192.
[14]	BAI Mingyu, CHEN Lili. Analytic death causes of liver cancer among urban residents in Yingkou city from 2015 to 2019 [J]. Journal of Practical Oncology, 2020, 34(6): 500-503.
[15]	BAI Yibing, YANG Jiani, FANG Lin, ZHANG Yanqiao. Research progress of wild-type gastrointestinal stromal tumors [J]. Journal of Practical Oncology, 2020, 34(6): 524-529.

Research progress of Egr1 in liver cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments